Stock comparison
Haemonetics
Medpace Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.88B
Sector
Healthcare
MEDP
Medpace Holdings
Market cap
$12.28B
Sector
Healthcare
Overall winner
Medpace Holdings MEDP
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | MEDP | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 61C | HAE |
| Benjamin Graham | 85A | 67B | HAE |
| Philip Fisher | 60C | 70B | MEDP |
| Peter Lynch | 54C | 65B | MEDP |
| Joel Greenblatt | 31F | 79B | MEDP |
| Charlie Munger | 54D | 67B | MEDP |
| Terry Smith | 55D | 75B | MEDP |
Side-by-side metrics
| Metric | HAE | MEDP |
|---|---|---|
| Market cap | $2.88B | $12.28B |
| P/E (TTM) | 24.8x | 25.7x |
| EV/EBIT | 14.1x | 21.2x |
| ROIC (TTM) | 8.37% | 56.06% |
| Gross margin | 55.74% | 29.07% |
| Net margin | 7.29% | 17.19% |
| Revenue CAGR 5y | 7.65% | 21.99% |
| EPS CAGR 5y | 24.62% | 32.59% |
| Debt / Equity | 1.5x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Gross margin55.74%vs 29.07%+48%
- EV/EBIT14.1xvs 21.2x+34%
MEDP leads on
- ROIC (TTM)56.06%vs 8.37%+85%
- Debt / Equity0.2xvs 1.5x+84%
- Market cap$12.28Bvs $2.88B+77%
- Revenue CAGR 5y21.99%vs 7.65%+65%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.